ABSTRACT
The synthesis and biological activity of novel derivatives of our previously reported IP receptor agonist FR181157 is described. SAR studies to replace the cyclohexene-linker of FR181157 led to the discovery of compound 1i (FR207845) as a potent non-prostanoid PGI2 mimetic with good oral bioavailability.
Subject(s)
Cross-Linking Reagents/chemistry , Cyclohexanes/chemistry , Epoprostenol/chemistry , Epoprostenol/pharmacology , Oxazoles/chemistry , Oxazoles/pharmacology , Receptors, Prostaglandin/agonists , Administration, Oral , Animals , Biomimetics , Cyclohexenes , Humans , Molecular Structure , Oxazoles/administration & dosage , Oxazoles/chemical synthesis , Platelet Aggregation/drug effects , Rats , Structure-Activity RelationshipABSTRACT
Synthetic and biological evaluation of novel diphenyloxazole derivatives containing a pyrrolidine ring, as a prostacyclin mimetic without the PG skeleton, are described. Asymmetric reduction of a ketone using a chiral Ru complex and reductive amination by NaBH(4) produces four isomers of the tetrahydronaphthalene ring and the pyrrolidine ring with high stereoselectivity. FR193262 (4), (R,R)-diphenyloxazolyl pyrrolidine derivative, displays high potency and agonist efficacy at the IP receptor and has good bioavailability in rats and dogs.
Subject(s)
Epoprostenol/antagonists & inhibitors , Oxazoles/chemical synthesis , Receptors, Prostaglandin/antagonists & inhibitors , Animals , Biological Availability , Dogs , Haplorhini , Humans , Inhibitory Concentration 50 , Molecular Mimicry , Oxazoles/pharmacokinetics , Oxazoles/pharmacology , Pyrrolidines , Rats , Receptors, Epoprostenol , Reducing Agents , Species Specificity , Structure-Activity RelationshipABSTRACT
The new classes of diphenylcarbamate derivatives with a tetrahydronaphthalene skeleton as highly potent and selective IP agonists have been discovered. The optimized diphenylcarbamate type compound FK-788: (R)-4 exhibited potent antiaggregative potency with an IC50 of 18 nM and high binding affinity for the human recombinant IP receptor with K(i) values of 20 nM and selectivity for human IP over all other members of the human prostanoid receptor family. Compound (R)-4 was shown to exhibit good pharmacokinetic properties in rats and dogs, and also good bioavailability in healthy volunteers.
Subject(s)
Carbamates/chemistry , Carbamates/pharmacology , Epoprostenol/metabolism , Molecular Mimicry , Platelet Aggregation/drug effects , Receptors, Prostaglandin/agonists , Administration, Oral , Animals , Carbamates/pharmacokinetics , Chlorocebus aethiops , Dogs , Humans , Proto-Oncogene Proteins c-met/blood , Rats , Receptors, Epoprostenol , Recombinant Proteins/agonists , Structure-Activity Relationship , Substrate SpecificityABSTRACT
Synthetic method of a novel prostaglandin (PG) mimetic: FR181175 without PG skeleton are described. The key to success is creation of a chiral epoxide using Sharpless AD reaction with high ee yield. FR181157 shows high potency and agonist efficacy at the IP receptor and has good bioavailability.
Subject(s)
Epoprostenol/pharmacokinetics , Oxazoles/pharmacokinetics , Administration, Oral , Animals , Area Under Curve , Epoprostenol/administration & dosage , Epoprostenol/chemical synthesis , Fasting , Models, Molecular , Molecular Conformation , Oxazoles/administration & dosage , Oxazoles/chemical synthesis , Stereoisomerism , Structure-Activity RelationshipABSTRACT
Novel NPY-Y5 antagonist FR73966 was discovered by screening of our in-house chemical library. The analogues were prepared by application of parallel synthesis techniques. Some of the resulting 2-oxobenzothiazolin-3-acetic acid derivatives exhibited nanomolar binding affinity for human NPY-Y5 receptors.
